Repligen Corp Gets a Hold Rating from Jefferies

By Carrie Williams

Jefferies analyst Brandon Couillard reiterated a Hold rating on Repligen Corp (NASDAQ: RGEN) yesterday and set a price target of $40. The company’s shares closed yesterday at $43.25, close to its 52-week high of $46.81.

According to, Couillard is a top 25 analyst with an average return of 23.8% and a 78.7% success rate. Couillard covers the Healthcare sector, focusing on stocks such as Bio-Rad Laboratories, Orasure Technologies, and DENTSPLY SIRONA Inc.

Repligen Corp has an analyst consensus of Hold, with a price target consensus of $40.

Based on Repligen Corp’s latest earnings report for the quarter ending March 31, the company posted quarterly revenue of $30.59 million and quarterly net profit of $3.07 million. In comparison, last year the company earned revenue of $25.09 million and had a net profit of $1.63 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Repligen Corp. engages on the development, production and commercialization of products used in the process of manufacturing biological drugs. It offers upstream solutions, downstream solutions, and analytics. The upstream solutions offers XCell ATF System and cell culture supplements.